<i>NRG1</i> Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in <i>KRAS</i> Wild-Type Pancreatic Ductal Adenocarcinoma

Abstract

This work adds to a growing body of evidence that <i>NRG1</i> gene fusions are recurrent, therapeutically actionable genomic events in pancreatic cancers. Based on the clinical outcomes described here, patients with <i>KRAS</i> wild-type tumors harboring <i>NRG1</i> gene fusions may benefit from treatment with afatinib.<i>See related commentary by Aguirre, p. 4589</i>.